Form 4: Halozyme Therapeutics SVP, Chief Legal Officer Reports Stock Transactions
SEC Form 4 Filing
Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, reports the vesting and settlement of restricted stock units and associated tax withholding.
Summary
- On February 23, 2025, Mark Howard Snyder, SVP, Chief Legal Officer of Halozyme Therapeutics, engaged in transactions involving Halozyme's common stock.
- 7,012 shares of common stock were acquired through the vesting and settlement of restricted stock units.
- 3,775 shares were disposed of to cover tax withholding obligations at a price of $57.75 per share.
- Following these transactions, Snyder directly owns 28,489 shares of common stock and 21,033 derivative securities.
Sentiment
Score: 5
Explanation: This is a neutral report of stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.
Industry Context
This filing is a routine disclosure of insider transactions, which are common for executives receiving stock-based compensation. It provides transparency into management's holdings and trading activity but doesn't necessarily indicate a change in the company's outlook.
Key Dates
| Date | Description |
|---|---|
| 02/23/2025 | Date of stock transactions: vesting of restricted stock units and tax withholding. |
| 02/24/2025 | Date of signature for the Form 4 filing. |
Keywords
Form 4, Halozyme Therapeutics, Stock Transactions, Restricted Stock Units, Beneficial Ownership, SVP, Chief Legal Officer, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.